9 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Top Stock Reports for Novartis, Zoom Video & Caterpillar http://www.zacks.com/research-daily/1059353/top-stock-reports-for-novartis-zoom-video-caterpillar?cid=CS-ZC-FT-research_daily-1059353 Sep 17, 2020 - Top Stock Reports for Novartis, Zoom Video & Caterpillar
All You Need to Know About Ahold NV (ADRNY) Rating Upgrade to Buy http://www.zacks.com/stock/news/1060450/all-you-need-to-know-about-ahold-nv-adrny-rating-upgrade-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-1060450 Sep 18, 2020 - Ahold NV (ADRNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights: Novartis, Zoom Video, Caterpillar, Microsoft, Cisco, Clorox and LHC Group http://www.zacks.com/stock/news/1060278/the-zacks-analyst-blog-highlights-novartis-zoom-video-caterpillar-microsoft-cisco-clorox-and-lhc-group?cid=CS-ZC-FT-press_releases-1060278 Sep 18, 2020 - The Zacks Analyst Blog Highlights: Novartis, Zoom Video, Caterpillar, Microsoft, Cisco, Clorox and LHC Group
Novartis Announces Data on Tafinlar, Mekinist & Piqray at ESMO http://www.zacks.com/stock/news/1061064/novartis-announces-data-on-tafinlar-mekinist-piqray-at-esmo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1061064 Sep 21, 2020 - Novartis (NVS) announces data from late-stage studies on Tafinlar, Mekinist and Piqray at ESMO 2020.
Novartis (NVS) Releases Positive Data on Enerzair Breezhaler http://www.zacks.com/stock/news/1055165/novartis-nvs-releases-positive-data-on-enerzair-breezhaler?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1055165 Sep 08, 2020 - Novartis (NVS) posts favorable data on asthma treatment Enerzair Breezhaler at the ERS International Congress 2020.
Novartis Reports Positive Data on Beovu for DME Indication http://www.zacks.com/stock/news/1058103/novartis-reports-positive-data-on-beovu-for-dme-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1058103 Sep 14, 2020 - Novartis (NVS) announces positive data on Beovu from an ongoing late-stage study for the DME indication.
Novartis' Eye Drug's Safety Label Update Approved by EMA http://www.zacks.com/stock/news/1058570/novartis-eye-drugs-safety-label-update-approved-by-ema?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1058570 Sep 15, 2020 - Novartis' (NVS) eye drug Beovu's safety label update receives approval from the Committee for Medicinal Products for Human Use.
Oxurion NV (TBGNF) CEO Patrik De Haes on Q2 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4375015-oxurion-nv-tbgnf-ceo-patrik-de-haes-on-q2-2020-results-earnings-call-transcript?source=feed_sector_transcripts Sep 17, 2020 - Oxurion NV (OTCPK:TBGNF) Q2 2020 Earnings Conference Call September 17, 2020 12:30 PM ET Company Participants Patrik De Haes - CEO Dominique Vanfleteren - CFO Andy De Deene - CDO Grace Chang - CMO Conference Call Participants Frédéric Gomez - Pharmium Sandra Cauwenberghs - KBC Securities Danny Van Quaethem - Econopolis Presentation Operator Good morning and good afternoon ladies and gentlemen.
Are Investors Undervaluing Ahold NV (ADRNY) Right Now? http://www.zacks.com/stock/news/1060408/are-investors-undervaluing-ahold-nv-adrny-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-1060408 Sep 18, 2020 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Pages: 1

Page 1